Exactly. Once supply gets tight, it becomes a manufacturing and access problem too—not just a shortage of the peptide itself. The whole supply chain gets dragged into it.
when pharmacies ration prescriptions, calling it merely a “peptide problem” seems like a convenient way to dodge the broader supply-chain and access failures.
Like when pharmacies have demand for the finished drugs but can’t get enough supply—are you pointing more to manufacturing capacity, or to the way distribution is being handled?
API manufacturing capacity is probably the more interesting bottleneck here—shortages expose how fragile the entire supply chain is, not just peptide synthesis.
API manufacturing capacity and injector availability can bottleneck GLP-1 supply separately from peptide production—are you pointing more to the device, distribution, or prescribing-side constraints?
Assuming this is mainly a manufacturing problem misses the insurance and pharmacy allocation mess—having supply somewhere doesn’t help if patients still can’t get coverage or find a dose locally.
Is the bigger bottleneck actually peptide production, or the delivery and distribution infrastructure around GLP-1s? Seems like the shortage exposes a much wider supply-chain problem.
Discussion 19